Business
Vertex Reports First Quarter 2025 Financial Results
— Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of...
About this update from Vortex Energy Corp.
[{"type":"text","content":"Vertex Reports First Quarter 2025 Financial Results\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwdoublebottom { border-bottom: double black 2.25pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadb4 { padding-bottom: 5px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl3 { padding-left: 15px }\n.bwpadl6 { padding-left: 30px }\n.bwpadr0 { padding-right: 0px }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth1 { width: 1% }\n.bwwidth100 { width: 100% }\n.bwwidth12 { width: 12% }\n.bwwidth13 { width: 13% }\n.bwwidth19 { width: 19% }\n.bwwidth2 { width: 2% }\n.bwwidth60 { width: 60% }\n.bwwidth71 { width: 71% }\n \n\n\n\n\n — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion —\n \n\n\n\n — Strong progress with CASGEVY\n \n\n ®\n \n\n , ALYFTREK™ and JOURNAVX™ launches —\n \n\n\n\n — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 —\n \n\n\n\n — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year —\n \n\n\n\n\n Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low end of its total revenue guidance range by $100 million, from $11.75 billion to $12 billion to a new range of $11.85 billion to $12 billion.\n \n\n “Vertex delivered a strong start to 2025 with notable execution across the business as we grow and diversify the revenue base, progress multiple launches and advance the R&D pipeline. We continued to expan...